1. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers

2. Program Goals

3. CheckMate-032 Nivolumab Monotherapy in Advanced/Metastatic GC/GEJ Cancer

4. CheckMate-032 (cont) Nivolumab Monotherapy in Advanced/Metastatic GC/GEJ Cancer

5. KEYNOTE-028 Pembrolizumab in Advanced Esophageal Carcinoma

6. KEYNOTE-028 (cont) Pembrolizumab in Advanced Esophageal Carcinoma

7. KEYNOTE-059 Pembrolizumab + 5-FU + Cisplatin in Advanced GC

8. KEYNOTE-059 (cont) Pembrolizumab + 5-FU + Cisplatin in Advanced GC

9. Avelumab in Advanced Gastric or GEJ Cancer

10. Avelumab in Advanced Gastric or GEJ Cancer (cont)

11. Phase 2 Study Nivolumab in Esophageal Cancer

12. Biomarker of Response

13. Future Directions GI Cancers

14. Abbreviations

15. Abbreviations (cont)